title: An update to "The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe".
abstract: A cost-effectiveness analysis of rotavirus vaccination in Belgium, England and Wales, Finland, France and the Netherlands published in 2009 was updated based on recent studies on rotavirus burden of disease and vaccine efficacy. All the qualitative conclusions in the previous study were found to remain valid. Vaccination remains cost-effective in Finland only when using plausible tender prices.
authors.forename: Mark
authors.initials: M
authors.lastname: Jit
authors.forename: Marie-Josée J
authors.initials: MJ
authors.lastname: Mangen
authors.forename: Hugues
authors.initials: H
authors.lastname: Melliez
authors.forename: Yazdan
authors.initials: Y
authors.lastname: Yazdanpanah
authors.forename: Joke
authors.initials: J
authors.lastname: Bilcke
authors.forename: Heini
authors.initials: H
authors.lastname: Salo
authors.forename: W John
authors.initials: WJ
authors.lastname: Edmunds
authors.forename: Philippe
authors.initials: P
authors.lastname: Beutels
mesh_terms: D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D005060:Europe / Q000453:epidemiology; D005759:Gastroenteritis / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control / Q000821:virology; D006801:Humans; D018803:Models, Economic; D012400:Rotavirus Infections / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control*; D022243:Rotavirus Vaccines / Q000191:economics*; D014611:Vaccination / Q000191:economics*
chemical_list: D022243:Rotavirus Vaccines